Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Immunic Inc Market Cap
The Immunic Inc (IMUX) share price is expected to increase by 898.88% over the next year. This is based on calculating the average 12-month share price estimate provided by 7 stock analysts who have covered IMUX. Price targets range from $5 at the low end to $28 at the high end. The current analyst consensus for IMUX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Immunic Inc has a total of 7 Wall St Analyst ratings. There are 7 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Immunic Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of IMUX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Matthew Caufield HC Wainwright & Co. | Buy | $10 | Initiates | Nov 25, 2024 |
| Jason Kolbert EF Hutton | Buy | $17 | Maintains | Nov 7, 2024 |
| Jason Kolbert EF Hutton | Buy | $17 | Maintains | Oct 22, 2024 |
| Jason Kolbert EF Hutton | Buy | $17 | Maintains | Sep 18, 2024 |
| Jason Kolbert EF Hutton | Buy | $17 | Initiates | Sep 16, 2024 |
| Faisal Khurshid Leerink Partners | Outperform | $5 | Assumes | Sep 9, 2024 |
| William Woods B. Riley Securities | Buy | $6 | Initiates | Aug 27, 2024 |
| Yasmeen Rahimi Piper Sandler | Overweight | $28 | Reiterates | Jul 16, 2024 |
| Tyler Bussian Brookline Capital | Buy | $10 | Initiates | Apr 5, 2024 |
| Andreas Argyrides Wedbush | Outperform | $7 | Maintains | Oct 10, 2023 |
| Andreas Argyrides Wedbush | Outperform | $5 | Reiterates | Jul 27, 2023 |
| Andreas Argyrides Wedbush | Outperform | $5 | Assumes | Jan 31, 2023 |
| Thomas Smith SVB Leerink | Market Perform | $5 | Downgrade | Oct 21, 2022 |
| Gobind Singh HC Wainwright & Co. | Buy | $26 | Assumes | Sep 19, 2022 |
| Nathan Weinstein Aegis Capital | Buy | $35 | Maintains | Aug 8, 2022 |
| Thomas Smith SVB Leerink | Outperform | $9 | Maintains | Jun 3, 2022 |
| Yasmeen Rahimi Piper Sandler | Overweight | $39 | Maintains | May 18, 2022 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $25 | Maintains | Sep 7, 2021 |
Aegis Capital | Buy | Initiates | Apr 15, 2021 | |
JMP Securities | Market Outperform | Initiates | Mar 24, 2021 |
When did it IPO
N/A
Staff Count
85
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Daniel Vitt Ph.D.
Market Cap
$115.3M
In 2023, IMUX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IMUX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Immunic, Inc. (Nasdaq: IMUX) CEO Daniel Vitt will speak at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024, at 11:30 am ET, discussing their therapeutic pipeline.
Why It Matters - Immunic's CEO participation in a major healthcare conference signals potential insights into the company's pipeline and strategy, which can influence stock performance and investor sentiment.
Sat, 16 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Immunic Inc (NASDAQ: IMUX) announced the publication of Phase 1 and Phase 1b clinical trial results for IMU-856 in The Lancet Gastroenterology & Hepatology.
Why It Matters - Publication of positive clinical trial results in a reputable journal can boost investor confidence and potentially increase the stock price of Immunic Inc.
Wed, 13 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Immunic Inc (NASDAQ:IMUX) published phase 1/1b trial data for IMU-856, targeting SIRT6 for celiac disease, in The Lancet Gastroenterology & Hepatology, led by Dr. James Daveson.
Why It Matters - The publication of clinical trial data in a reputable journal validates IMU-856's potential, potentially boosting investor confidence and interest in Immunic Inc.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Immunic, Inc. has published Phase 1/1b trial data for IMU-856, targeting SIRT6, in The Lancet Gastroenterology & Hepatology, focusing on healthy subjects and celiac disease patients.
Why It Matters - Publication of Phase 1 data in a prestigious journal enhances credibility, potentially attracting investors and increasing stock value for Immunic, Inc. as it advances in clinical trials.
Sat, 09 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Immunic, Inc. (NASDAQ: IMUX) will hold its Q3 2024 earnings conference call on November 7, 2024, at 8:00 AM ET, featuring key company executives and analysts.
Why It Matters - Immunic's Q3 earnings call may reveal financial performance, strategic updates, and future outlook, influencing stock valuation and investor sentiment.
Thu, 07 Nov 2024
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Immunic Inc (NASDAQ:IMUX) reported over $59 million in cash at Q3 2024, advancing key clinical trials for its lead MS candidate, IMU-838, including phase 2 and phase 3 studies.
Why It Matters - Immunic's strong cash position and progress in key clinical trials for its lead MS treatment could enhance its market potential, impacting stock performance and investor confidence.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
